Drug Trial Radar · NCT00305162
A Clinical Trial to Demonstrate the Efficacy of Cangrelor
Last checked: Nov 20, 2026Latest source record: May 8, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
8,882
Actual
Start
Apr 2006
Primary completion
May 2009
Study completion Jun 2010
Sponsor
- Lead sponsor
- The Medicines CompanyIndustry
- Sponsor type
- Industry
- First posted
- Mar 21, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to demonstrate that the efficacy of cangrelor is superior, or at least non-inferior, to that of clopidogrel in subjects requiring PCI.
Conditions
- Myocardial Infarction (MI)
- Acute Coronary Syndromes (ACS)
Interventions
Cangrelor (P2Y12 inhibitor)Drug
IV bolus (30 mcg/kg) \& infusion (4 mcg/kg/min) initiated prior to PCI, as soon as possible following randomization (after need for PCI is confirmed) but not more than 30 minutes prior to placement of arterial access. Infusion is to continue for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion).
clopidogrel (oral P2Y12 inhibitor)Drug
600 mg active clopidogrel administered as soon as possible following randomization (after need for PCI confirmed), but not more than 30 minutes prior to the placement of the arterial access.
Placebo bolus & placebo infusionDrug
placebo bolus (30 mcg/kg) \& placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
Placebo capsules - end of infusionDrug
Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing
Placebo capsules - as soon as possible after randomizationDrug
Placebo capsules given as soon as possible after randomization to mimic 600mg clopidogrel dosing
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of All-cause Mortality, Myocardial Infarction (MI), and Ischemia-driven Revascularization (IDR)Time frame: randomization through 48 hours after randomization
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pennsylvania Hospital
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.